Feature | January 21, 2015

Real-World Data Show Consistent Safety Performance of Once-Daily Rivaroxaban

Results indicate few cases of major bleeding and only in older patient

rivaroxaban, Xarelto, safety performance, Janssen, NVAF

January 21, 2015 — A new post-marketing study evaluating the safety of once-daily rivaroxaban (Xarelto) shows, in patients with non-valvular atrial fibrillation (NVAF), rates and patterns of major bleeding in routine clinical practice are generally consistent with those observed in Phase 3 clinical trials used to approve the medicine for this indication. These 15-month results, published in Clinical Cardiology, represent initial findings from an ongoing, five-year observational study of patients using rivaroxaban daily over the course of their lives.  

“These findings reaffirm the safety profile of rivaroxaban,” said W. Frank Peacock (co-author of the manuscript), M.D., FACEP, associate chair and research director, emergency medicine, Baylor College of Medicine. “We anticipate future findings from this five-year observational study will continue to provide real-world information about the use of Xarelto in routine clinical practice.”

Researchers analyzed data from Jan. 1, 2013, to March 31, 2014, using U.S. Department of Defense (DoD) integrated electronic healthcare records via a collaboration with Health ResearchTx LLC (HRTX) to evaluate major bleeding rates in NVAF patients treated with rivaroxaban in the real-world clinical setting. Of the 27,467 patients receiving rivaroxaban, an incidence of major bleeding was observed at 2.86 per 100 person-years, which was generally consistent with rates reported in the ROCKET-AF clinical trial. Additionally, patients who experienced major bleeding were older (with a mean age of 78) and fatal outcomes were rare.

Janssen Pharmaceuticals Inc. designed the study in conjunction with DoD and HRTX and in agreement with the U.S. Food and Drug Administration (FDA) to proactively ascertain, analyze and report potential side effects with rivaroxaban use;  these included major bleeding events, associated risk factors and bleeding-related clinical outcomes in NVAF patients receiving rivaroxaban. Major bleeding cases for this study were ascertained using a validated Cunningham (2011) algorithm, which was generally consistent with but not identical to the definition of major bleeding used in clinical studies, because it relied on retrospectively identified electronic medical records. While the results are not intended for any direct comparison, these data show rates and patterns of major bleeding were generally consistent with those reported in the previous large randomized FDA registration trial of rivaroxaban.

For more information: www.xarelto-us.com

Related Content

Surgery Could Reduce Frailty in Adults With Heart Failure
News | Heart Failure| November 17, 2017
November 17, 2017 — Common practice, and recently published research, shows that the risk of complications with surge
News | Antiplatelet and Anticoagulation Therapies| November 16, 2017
Bristol-Myers Squibb Company and Pfizer Inc. released real-world data (RWD) of outcomes associated with direct oral...
SPRINT Trial Data Support New AHA/ACC Hypertension Guidelines
News | Hypertension| November 16, 2017
Findings from a landmark study funded by the National Institutes of Health (NIH) support a key component of the new...
Videos | FFR Technologies| November 15, 2017
A discussion with William Fearon, M.D.
Philips Azurion Image-Guided Therapy Platform Improves Clinical Workflow for Interventional Procedures
News | Angiography| November 15, 2017
Philips announced the results of a comprehensive, independent, two-year study demonstrating the clinical workflow...
Videos | Heart Valve Technology| November 15, 2017
Ted Feldman, M.D., MSCAI FACC FESC, director of the cardiac cath lab, Evanston Hospital, is the principal investigato
Videos | Left Atrial Appendage (LAA) Occluders| November 14, 2017
Vivek Reddy, M.D., director of cardiac arrhythmia services and professor of medicine, cardiology, Mount Sinai Hospita
News | Heart Failure| November 13, 2017
November 10, 2017 — Moderna Therapeutics announced a new license and collaboration with AstraZeneca to co-develop and
Mexican Doctors Safely Reuse Donated Pacemakers After Sterilization
News | Pacemakers| November 10, 2017
Mexican doctors have safely reused donated pacemakers after sterilization, shows a study presented at the 30th Mexican...
Overlay Init